肝細胞癌藥物市場規模、佔有率、成長分析（按藥物類別、治療類型、治療類型、給藥途徑、最終用戶、分銷管道和地區分類）- 產業預測，2025 年至 2032 年

2023 年全球肝細胞癌藥物市場規模為 14 億美元，預計將從 2024 年的 15.2 億美元成長到 2032 年的 28.7 億美元，預測期內（2025-2032 年）的複合年成長率為 8.3%。

隨著患者人口結構的變化、政府在腫瘤學方面的支出增加以及標靶治療的進步，全球肝細胞癌 (HCC) 治療市場正在經歷顯著成長。全球對醫療創新的投資正在加速新療法的採用，尤其是針對肝癌的精準藥物。早期診斷的增加以及免疫療法和聯合治療的採用不斷增加，正在擴大整個醫療保健系統中 HCC 治療的可用性。精準腫瘤學領域的顯著創新，例如生物標記引導治療和下一代蛋白酪氨酸激酶抑制劑 (TKI)，正在為 HCC 治療的突破鋪平道路。此外，人工智慧驅動的藥物發現平台正在促進有前景的新型免疫療法的快速發展，進一步增強了市場的前景。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究

肝細胞癌藥物市場規模（按藥物類別和複合年成長率） (2025-2032)

• 市場概覽
• PD-1/PD-L1抑制劑
• 蛋白酪氨酸激酶抑制劑

肝細胞癌藥物市場規模（依治療類型和複合年成長率） (2025-2032)

• 市場概覽
• 標靶治療
• 免疫療法
• 其他

肝細胞癌藥物市場規模（依治療類型和複合年成長率） (2025-2032)

• 市場概覽
• 藥物治療、手術
• 放射線治療
• 化療
• 其他

肝細胞癌藥物市場規模（依給藥途徑及複合年成長率） (2025-2032)

• 市場概覽
• 口服
• 注射
• 其他

肝細胞癌藥物市場規模（按最終用戶和複合年成長率） (2025-2032)

• 市場概覽
• 醫院
• 居家護理
• 專科診所
• 其他

肝細胞癌藥物市場規模（依分銷管道分類）及複合年成長率（2025-2032）

• 市場概覽
• 醫院藥房
• 網路藥局
• 零售藥局

肝細胞癌藥物市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益同比對比（2022-2024 年）

主要企業簡介

• Exelixis, Inc.（US）
• Merck & Co., Inc.（US）
• AstraZeneca（UK）
• Bristol-Myers Squibb Company（US）
• Eli Lilly and Company（US）
• SillaJen, Inc.（South Korea）
• Bayer AG（Germany）
• Janssen Global Services, LLC（US）
• Pfizer Inc.（US）
• F. Hoffmann-La Roche Ltd（Switzerland）
• Gilead Sciences, Inc.（US）
• GSK plc（UK）
• Takeda Pharmaceutical Company Limited（Japan）
• Amgen Inc.（US）
• Polaris Group（US）
• Hepion Pharmaceuticals, Inc.（US）
• Provectus Biopharmaceuticals, Inc.（US）

結論和建議

Global Hepatocellular Carcinoma Drugs Market size was valued at USD 1.4 billion in 2023 and is poised to grow from USD 1.52 billion in 2024 to USD 2.87 billion by 2032, growing at a CAGR of 8.3% during the forecast period (2025-2032).

The global hepatocellular carcinoma (HCC) drugs market is experiencing significant growth, driven by evolving patient demographics, increased government expenditure on oncology, and advancements in targeted therapies. Worldwide investments in health innovation are accelerating the adoption of new treatments, particularly precision medicine dedicated to liver cancer. The rise of early diagnoses, along with the growing implementation of immunotherapies and combination therapies, is expanding the utilization of HCC medications across healthcare delivery systems. Notable innovations in precision oncology, including biomarker-guided therapies and next-generation tyrosine kinase inhibitors (TKIs), are paving the way for breakthroughs in HCC treatment. Additionally, artificial intelligence-driven drug discovery platforms are facilitating the rapid development of promising new immunotherapies, further enhancing the market's prospects.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hepatocellular Carcinoma Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Hepatocellular Carcinoma Drugs Market Segments Analysis

Global Hepatocellular Carcinoma Drugs Market is segmented by Drug Class, Therapy Type, Treatment Type, Route of Administration, End-Users, Distribution Channel and region. Based on Drug Class, the market is segmented into PD-1/PD-L1 Inhibitors and Tyrosine Kinase Inhibitors. Based on Therapy Type, the market is segmented into Targeted Therapy, Immunotherapy and Others. Based on Treatment Type, the market is segmented into Medication, Surgery, Radiotherapy, Chemotherapy and Others. Based on Route of Administration, the market is segmented into Oral, Injectable and Others. Based on End-Users, the market is segmented into Hospitals, Homecare, Specialty Clinics and Others. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Online Pharmacy and Retail Pharmacy. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Hepatocellular Carcinoma Drugs Market

The global hepatocellular carcinoma (HCC) drugs market is largely driven by the rising incidence of HCC globally, largely due to chronic hepatitis B and C infections that are becoming resistant to treatment. Additionally, increasing alcohol consumption and the prevalence of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH), which are linked to the growing rates of obesity and diabetes, contribute to this upward trend. With a substantial and expanding patient population requiring effective treatment options, there is a consistent demand for both existing therapies and newly developed drugs to address this pressing health challenge.

Restraints in the Global Hepatocellular Carcinoma Drugs Market

The global hepatocellular carcinoma drugs market faces significant obstacles primarily due to the high costs associated with immunotherapies and targeted treatments, which restrict access for patients, particularly in low- and middle-income nations. Additionally, established markets implement stringent health technology assessment (HTA) policies, such as those from NICE and IQWiG, which require lengthy evaluations before providing reimbursement for expensive therapies. This can further limit patient access and delay the introduction of innovative treatments, despite their proven clinical efficacy, thereby hindering the overall growth and development of the market for hepatocellular carcinoma drugs.

Market Trends of the Global Hepatocellular Carcinoma Drugs Market

The Global Hepatocellular Carcinoma (HCC) drug market is witnessing a significant trend towards the rapid expansion of combination therapies, particularly involving PD-1/PD-L1 inhibitors alongside Tyrosine Kinase Inhibitors (TKIs) and anti-angiogenic agents. Notable combinations, such as Roche's Tecentriq (atezolizumab) with Avastin (bevacizumab), have demonstrated remarkable clinical efficacy, including a 42% reduction in mortality risk as observed in the IMbrave150 trial. This trend is further propelled by accelerated approval processes from regulatory bodies like the FDA and EMA, amplifying market growth potential. As clinical outcomes improve, the demand for effective HCC treatments continues to rise, reshaping the landscape of oncological therapies.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Studies

Global Hepatocellular Carcinoma Drugs Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• PD-1/PD-L1 Inhibitors
• Tyrosine Kinase Inhibitors

Global Hepatocellular Carcinoma Drugs Market Size by Therapy Type & CAGR (2025-2032)

• Market Overview
• Targeted Therapy
• Immunotherapy
• Others

Global Hepatocellular Carcinoma Drugs Market Size by Treatment Type & CAGR (2025-2032)

• Market Overview
• Medication, Surgery
• Radiotherapy
• Chemotherapy
• Others

Global Hepatocellular Carcinoma Drugs Market Size by Route of Administration & CAGR (2025-2032)

• Market Overview
• Oral
• Injectable
• Others

Global Hepatocellular Carcinoma Drugs Market Size by End-Users & CAGR (2025-2032)

• Market Overview
• Hospitals
• Homecare
• Specialty Clinics
• Others

Global Hepatocellular Carcinoma Drugs Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Global Hepatocellular Carcinoma Drugs Market Size & CAGR (2025-2032)

• North America (Drug Class, Therapy Type, Treatment Type, Route of Administration, End-Users, Distribution Channel)
  • US
  • Canada
• Europe (Drug Class, Therapy Type, Treatment Type, Route of Administration, End-Users, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Drug Class, Therapy Type, Treatment Type, Route of Administration, End-Users, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Drug Class, Therapy Type, Treatment Type, Route of Administration, End-Users, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Drug Class, Therapy Type, Treatment Type, Route of Administration, End-Users, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Exelixis, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SillaJen, Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Janssen Global Services, LLC (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Polaris Group (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hepion Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Provectus Biopharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations